We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nasdaq (NDAQ) to Report Q1 Earnings: What's in the Cards?
Read MoreHide Full Article
Nasdaq, Inc.NDAQ is slated to report first-quarter 2020 results on Apr 22, before market open. In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate by 1.57%, led by higher revenues.
Let’s see how things have shaped up for the upcoming announcement.
Nasdaq’s first-quarter results are likely to reflect expansion of index and analytics businesses, higher listing business and lower interest expenses.
Nasdaq’s first-quarter results are also expected to reflect the contribution of new eVestment products, Research Management and Market Lens and Quandl acquisition.
Non-trading revenues are likely to have benefited from improved performance of Market Technology, continued solid growth of Index and Investment Data & Analytics businesses.
Market Technology and Information Services businesses offer the biggest growth opportunities. Organic growth, Cinnober acquisition, higher software delivery and higher index and growing listing business are likely to have driven revenues. The Zacks Consensus Estimate for Marketing Information Service revenues is pegged at $199 million, indicating an increase of 3.1% from the year-ago reported figure.
Higher listings are expected to have aided revenues. In the first quarter, there were 4,185 listed companies on Nasdaq compared with 4,077 in the year-ago period. Total listings grew 2.6% year over year to 4,185. The Zacks Consensus Estimate for listing services revenues is pegged at $74 million, indicating 4.2% increase from the year-ago period reported figure.
Interest expenses are likely to have decreased due to lower outstanding debt obligations as well as refinancing of the 2020 Notes with 2029 Notes at a lower interest rate.
Sustained share buyback is likely to have provided additional boost to the bottom line.
The Zacks Consensus Estimate for earnings is pegged at $1.43, indicating 17.2% increase from the year-ago period reported figure.
Earnings Surprise History
The company boasts an attractive earnings surprise history, having surpassed estimates in each of the trailing four quarters, the positive surprise being 3.33%, on average. This is depicted in the chart below:
Our proven model predicts an earnings beat for Nasdaq this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.
Earnings ESP: Nasdaq has an Earnings ESP of +1.15%. This is because the Most Accurate Estimate of $1.45 is higher than the Zacks Consensus Estimate of $1.43. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Nasdaq carries a Zacks Rank #3.
Other Stocks to Consider
Here are some other stocks from the finance sector with the perfect combination of elements to surpass estimates in their upcoming releases.
Flagstar Bancorp, Inc. is set to report first-quarter earnings on Apr 28. The stock has an Earnings ESP of +0.26% and a Zacks Rank #3.
OceanFirst Financial Corp. (OCFC - Free Report) is set to report first-quarter earnings on Apr 23. The stock has an Earnings ESP of +6.94% and a Zacks Rank of 3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Nasdaq (NDAQ) to Report Q1 Earnings: What's in the Cards?
Nasdaq, Inc. NDAQ is slated to report first-quarter 2020 results on Apr 22, before market open. In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate by 1.57%, led by higher revenues.
Let’s see how things have shaped up for the upcoming announcement.
Nasdaq’s first-quarter results are likely to reflect expansion of index and analytics businesses, higher listing business and lower interest expenses.
Nasdaq’s first-quarter results are also expected to reflect the contribution of new eVestment products, Research Management and Market Lens and Quandl acquisition.
Non-trading revenues are likely to have benefited from improved performance of Market Technology, continued solid growth of Index and Investment Data & Analytics businesses.
Market Technology and Information Services businesses offer the biggest growth opportunities. Organic growth, Cinnober acquisition, higher software delivery and higher index and growing listing business are likely to have driven revenues. The Zacks Consensus Estimate for Marketing Information Service revenues is pegged at $199 million, indicating an increase of 3.1% from the year-ago reported figure.
Higher listings are expected to have aided revenues. In the first quarter, there were 4,185 listed companies on Nasdaq compared with 4,077 in the year-ago period. Total listings grew 2.6% year over year to 4,185. The Zacks Consensus Estimate for listing services revenues is pegged at $74 million, indicating 4.2% increase from the year-ago period reported figure.
Interest expenses are likely to have decreased due to lower outstanding debt obligations as well as refinancing of the 2020 Notes with 2029 Notes at a lower interest rate.
Sustained share buyback is likely to have provided additional boost to the bottom line.
The Zacks Consensus Estimate for earnings is pegged at $1.43, indicating 17.2% increase from the year-ago period reported figure.
Earnings Surprise History
The company boasts an attractive earnings surprise history, having surpassed estimates in each of the trailing four quarters, the positive surprise being 3.33%, on average. This is depicted in the chart below:
Nasdaq, Inc. Price and EPS Surprise
Nasdaq, Inc. price-eps-surprise | Nasdaq, Inc. Quote
What Our Quantitative Model States
Our proven model predicts an earnings beat for Nasdaq this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.
Earnings ESP: Nasdaq has an Earnings ESP of +1.15%. This is because the Most Accurate Estimate of $1.45 is higher than the Zacks Consensus Estimate of $1.43. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Nasdaq carries a Zacks Rank #3.
Other Stocks to Consider
Here are some other stocks from the finance sector with the perfect combination of elements to surpass estimates in their upcoming releases.
Banner Corporation (BANR - Free Report) is set to report first-quarter earnings on Apr 27. The stock has an Earnings ESP of +10.12% and a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Flagstar Bancorp, Inc. is set to report first-quarter earnings on Apr 28. The stock has an Earnings ESP of +0.26% and a Zacks Rank #3.
OceanFirst Financial Corp. (OCFC - Free Report) is set to report first-quarter earnings on Apr 23. The stock has an Earnings ESP of +6.94% and a Zacks Rank of 3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>